Biofarm S.A. Sustainability Profile
Biofarm S.A., a prominent player in the pharmaceutical industry, is headquartered in Romania (RO) and has established a significant presence across various operational regions. Founded in 1991, the company has achieved notable milestones, including the expansion of its product portfolio and the enhancement of its manufacturing capabilities. Specialising in the development and production of high-quality generic medicines, Biofarm S.A. is recognised for its commitment to innovation and quality. The company’s core offerings include a diverse range of pharmaceuticals, particularly in the fields of cardiology, dermatology, and gynaecology, setting it apart with its rigorous adherence to international standards. With a strong market position, Biofarm S.A. has garnered numerous accolades for its contributions to healthcare, making it a trusted name among healthcare professionals and patients alike.
DitchCarbon Score
How does Biofarm S.A.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Biofarm S.A.'s score of 20 is lower than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Biofarm S.A.'s reported carbon emissions
Biofarm S.A., headquartered in Romania, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Biofarm S.A. may not have established formal commitments to reduce its carbon footprint or engage in industry-standard climate initiatives such as the Science Based Targets initiative (SBTi) or the Carbon Disclosure Project (CDP). In the context of the pharmaceutical industry, where sustainability and climate action are increasingly critical, Biofarm S.A. may need to consider developing a comprehensive strategy to address carbon emissions and set measurable reduction targets. This could enhance their environmental responsibility and align with global climate goals.
How Carbon Intensive is Biofarm S.A.'s Industry?
How Carbon Intensive is Biofarm S.A.'s Location?
Biofarm S.A.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Biofarm S.A. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
